WebMD provides information about interactions between Humira Pen Psoriasis Starter Pack subcutaneous and tumor-necrosis-factor-tnf-inhibitors-interleukin-1-blocker. WebMD provides information about common drug or vitamin interactions for Humira Pen Psoriasis Starter Pack subcutaneous. Tumor Necrosis Factor inhibitor – Humira is a human monoclonal antibody (IgG) specific for human tumor necrosis factor alpha (TNF-alpha). Malignancies – TNF inhibitors may increase the risk for certain cancers, particularly lymphoma. Interleukin-1-receptor inhibitor – Kineret is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra).
Tumor necrosis factor (TNF) is a cytokine, a signaling chemical released by immune cells to activate other immune cells. TNF blockers are immunosuppressive agents approved to treat immune system diseases, including juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ankylosing spondylitis. Etanercept (Enbrel) infliximab (Remicade), Efalizumab and Adalimumab (Humira) block the action of tumor necrosis factor, and can reduce disease activity in patients with inflammatory diseases. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. 2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis – The recommended dose of HUMIRA for. HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Categories of biologics include anti-tumor necrosis factor (anti-TNF) drugs, also called TNF inhibitors; interleukin-1 blockers; T cell blockers; Doctors often start by prescribing an anti-TNF drug (which include Enbrel, Humira, Cimzia, Simponi, and Remicade), but ultimately the choice is made based on what works best for the person taking the drug. The first biologic approved for RA, Enbrel is also approved for plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis (JIA), and ankylosing spondylitis. It requires self-injection once every two weeks using either a preloaded pen or a preloaded syringe.
Does the client have a diagnosis of ankylosing spondylitis, Crohn s disease, psoriatic arthritis and/or rheumatoid arthritis in the last 730 days? Does the client have 1 claim for an interleukin-1 (IL-1) inhibitor or a tumor necrosis factor (TNF) blocker in the last 14 days? HUMIRA adalimumab 40 mg in 0.8 ml sterile solution (50 mg/ml) subcutaneous injection.
Drug Prescriptions For Arthritis